Get Reviva Pharmaceuticals alerts:Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH – Free Report) – Stock analysts at Chardan Capital issued their FY2025 earnings per share estimates for shares of Reviva Pharmaceuticals in a research report issued on Monday, September 29th. Chardan Capital currently has a “Buy” rating and a $2.00 price objective on the stock. The consensus estimate for Reviva Pharmaceuticals’ current full-year earnings is ($0.97) per share. Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) last announced its quarterly earnings results on Thursday, August 14th. Featured StoriesReceive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.